10 February 2014 -  Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Health Canada has granted a Notice of Compliance approving Juxtapid as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce low-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia.

For more details, go to: http://ir.aegerion.com/releasedetail.cfm?ReleaseID=824406